Announcements Trials
Browse Landscape

Phase

Phase 2 64Phase 1 25Phase 1/2 18Phase NA 5Phase 3 4Phase EARLY_PHASE1 3Phase 4 3

Status

Completed 22Recruiting 9Unknown 8Not yet recruiting 6Withdrawn 3Terminated 2Active not recruiting 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Breast Neoplasms 10Neoplasms 9Polycystic Ovary Syndrome 8Infertility 5Liver Neoplasms 4Pain, Postoperative 3Neoplasm Metastasis 3Multiple Myeloma 3Lung Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Recurrence 2Pulmonary Embolism 2Prostatic Neoplasms 2Pleural Effusion 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neuroma, Acoustic 2Melanoma 2Lymphoma, Follicular 2Leiomyoma 2Inflammation 2Febrile Neutropenia 2Colorectal Neoplasms 2Bites and Stings 2Anovulation 2Vomiting 1Venous Thrombosis 1Venous Thromboembolism 1

Interventions

pomalidomide 1ixazomib 1Zoledronic Acid 1Lenalidomide 1Kyphoplasty 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Withdrawn × Multiple Myeloma × Clear all
NCT05183139 2022-05-03

US MM-7

Takeda

Phase 4 Withdrawn
Plasma cell

Multiple Myeloma

NCT01410929 2017-01-20

MM

Merit Medical Systems, Inc.

Phase 4 Withdrawn
Plasma cell

Back Pain, Multiple Myeloma, Neoplasms

NCT00242528 2015-04-14

Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.

Novartis

Phase 4 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡